ITEM 5.02 Departure of Principal Officer; Appointment of Principal Officer

(d) Appointment of Principal Officers

On June 30, 2020, Mr. Robert Dickey IV was appointed as an Independent Member of the Board of Directors.

Mr. Dickey is currently the Managing Director at Foresite Advisors, a financial advisory firm for life science companies that is based in Philadelphia. He is also on the Board and is Audit Committee Chair of Emmaus Life Sciences (EMMA) and is part of the Leadership Team at Cell One Partners Inc. He has more than 25 years of experience, primarily as a CFO or a Board member, leading life science and medical device companies, both private and public, ranging from early-stage development to commercial operations. Advisory clients have included Aclipse, Panorama Medicine, Carisma, Vallon, NLS Pharmaceutics, Mercaptor, BeyondSpring and Sharp Edge Labs. Prior to becoming an advisor he served as full time CFO for multiple companies, including Caladrius Biosciences (CLBS), Tyme Technologies (TYME), StemCyte, Locus Pharmaceuticals and Protarga, Inc., among others. He also served on the Boards of Sanuthera and Protarga, which he sold to Daiichi Sankyo. Before that he spent 18 years in investment banking, mostly at Lehman Brothers, with a background split between M&A and capital markets transactions. Rob holds an AB from Princeton University and an MBA from The Wharton School, University of Pennsylvania.

Mr. Dickey is experienced in all stages of the corporate lifecycle, including start-up operations, going public, high growth, turnarounds and exit strategies.

His expertise includes public and private financings, M&A, partnering/licensing transactions, project management, managing company's finance and accounting functions, and Chapter 11 reorganizations, as well as interactions with Boards, venture capitalists, shareholders and Wall Street.

© Edgar Online, source Glimpses